HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia.

Abstract
X-linked hypophosphatemia (XLH), characterized by renal phosphate wasting, is the most common cause of vitamin D-resistant rickets. It has been postulated that some phosphaturic factor plays a causative role in XLH and its murine homolog, the Hyp mouse. Fibroblast growth factor 23 (FGF23) is a physiological phosphaturic factor; its circulatory level is known to be high in most patients with XLH and Hyp mice, suggesting its pathophysiological role in this disease. To test this hypothesis, we treated Hyp mice with anti-FGF23 antibodies to inhibit endogenous FGF23 action. A single injection of the antibodies corrected the hypophosphatemia and inappropriately normal serum 1,25-dihydroxyvitamin D. These effects were accompanied by increased expressions of type IIa sodium-phosphate cotransporter and 25-hydroxyvitamin-D-1alpha-hydroxylase and a suppressed expression of 24-hydroxylase in the kidney. Repeated injections during the growth period ameliorated the rachitic bone phenotypes typically observed in Hyp mice, such as impaired longitudinal elongation, defective mineralization, and abnormal cartilage development. Thus, these results indicate that excess actions of FGF23 underlie hypophosphatemic rickets in Hyp mice and suggest a novel therapeutic potential of the FGF23 antibodies for XLH.
AuthorsYukiko Aono, Yuji Yamazaki, Junichi Yasutake, Takehisa Kawata, Hisashi Hasegawa, Itaru Urakawa, Toshiro Fujita, Michihito Wada, Takeyoshi Yamashita, Seiji Fukumoto, Takashi Shimada
JournalJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (J Bone Miner Res) Vol. 24 Issue 11 Pg. 1879-88 (Nov 2009) ISSN: 1523-4681 [Electronic] United States
PMID19419316 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies
  • Fgf23 protein, mouse
  • Vitamin D
  • Fibroblast Growth Factors
  • Fibroblast Growth Factor-23
Topics
  • Aging (drug effects, pathology)
  • Animals
  • Antibodies (administration & dosage, pharmacology, therapeutic use)
  • Body Weight (drug effects)
  • Familial Hypophosphatemic Rickets (blood, complications, drug therapy, urine)
  • Female
  • Fibroblast Growth Factor-23
  • Fibroblast Growth Factors (immunology)
  • Genetic Diseases, X-Linked
  • Growth Plate (drug effects, pathology)
  • Immunohistochemistry
  • Injections, Subcutaneous
  • Male
  • Mice
  • Osteomalacia (blood, complications, drug therapy, urine)
  • Tibia (drug effects, pathology)
  • Time Factors
  • Vitamin D (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: